The opportunities and challenges of the disease-modifying immunotherapy for type 1 diabetes: A systematic review and meta-analysisChu Lin, Linong Ji, Wenjia Yang et al.|Pharmacological Research|2024Cited by 16
One or two? Comparison of the cardiorenal effects between combination therapy and monotherapy with <scp>SGLT2i</scp> or <scp>GLP1RA</scp>Mengqing Zhang, Linong Ji, Chu Lin et al.|Diabetes Obesity and Metabolism|2024Cited by 12